Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4999-5004

  Van Der Elst, Kim C M ^a   Span, Lambert F R ^a   Van Hateren, Kai ^a   Vermeulen, Karin M ^a   Van Der Werf, Tjip S ^a   Greijdanus, Ben ^a   Kosterink, Jos G W ^a,b   Uges, Donald R A ^a   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACCURACY; ADULT; AGED; ANALYTIC METHOD; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BLOOD SAMPLING; BLOOD VOLUME; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; CANDIDIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG MONITORING; FEMALE; HEMATOCRIT; HUMAN; INVASIVE ASPERGILLOSIS; MALE; MYCOSIS; PAIN; PAIN ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; ROOM TEMPERATURE; STEADY STATE; VENOUS BLOOD;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRIED BLOOD SPOT TESTING; DRUG MONITORING; FLUCONAZOLE; HUMANS; MIDDLE AGED; MUCORMYCOSIS; MYCOSES; TRIAZOLES; YOUNG ADULT;

EID: 84884229033     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00707-13     Document Type: Article

References (42)

1. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF, Infectious Diseases Society of America. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360. doi:10.1086/525258.
2. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177. doi:10 .1086/378745.
3. Eggimann P, Garbino J, Pittet D. 2003. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis. 3:685-702.
4. Kim A, Nicolau DP, Kuti JL. 2011. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses 54:e301- e312. doi:10.1111/j.1439-0507.2010 .01903.x.
5. Tong KB, Lau CJ, Murtagh K, Layton AJ, Seifeldin R. 2009. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int. J. Infect. Dis. 13:24-36. doi:10.1016/j.ijid.2008.02 .013.
6. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34. doi:10.1128/AAC.00705-08.
7. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31. doi:10.1086/504810.
8. Morrell M, Fraser VJ, Kollef MH. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645. doi:10.1128/AAC.49.9.3640-3645.2005.
9. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, and Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. doi:10.1086/596757.
10. Alffenaar JW, de Vos T, Uges DR, Daenen SM. 2009. High voriconazole trough levels in relation to hepatic function: how to adjust the dosage? Br. J. Clin. Pharmacol. 67:262-263. doi:10.1111/j.1365-2125.2008.03315.x.
11. Brüggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48:1441-1458. doi:10.1086/598327.
12. Hope WW, Billaud EM, Lestner J, Denning DW. 2008. Therapeutic drug monitoring for triazoles. Curr. Opin. Infect. Dis. 21:580-586. doi:10 .1097/QCO.0b013e3283184611.
13. Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O. 2012. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokineticsbased analysis of adult patients with invasive fungal infections. Clin. Infect. Dis. 55:381-390. doi:10.1093/cid/cis437.
14. Dolton MJ, Ray JE, Chen SC, Ng K, Pont LG, McLachlan AJ. 2012. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:4793-4799. doi:10.1128 /AAC.00626-12.
15. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. doi:10.1086/524669.
16. Troke PF, Hockey HP, Hope WW. 2011. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob. Agents Chemother. 55:4782-4788. doi:10 .1128/AAC.01083-10.
17. Dolton MJ, Ray JE, Chen SC, Ng K, Pont L, McLachlan AJ. 13 August 2012. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob. Agents Chemother. doi:10.1128/AAC.00802-12.
18. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. 2012. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob. Agents Chemother. 56:2806-2813. doi:10.1128 /AAC.05900-11.
19. Green MR, Woolery JE. 2011. Optimising absorption of posaconazole. Mycoses 54:e775- e779. doi:10.1111/j.1439-0507.2011.02020.x.
20. Jang SH, Colangelo PM, Gobburu JV. 2010. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88:115-119. doi:10.1038/clpt.2010.64.
21. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE, Infectious Diseases Society of America. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189. doi:10.1086 /380796.
22. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. 2005. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49:3171-3177. doi:10.1128/AAC.49.8.3171-3177.2005.
23. Wade KC, Benjamin DK, Jr, Kaufman DA, Ward RM, Smith PB, Jayaraman B, Adamson PC, Gastonguay MR, Barrett JS. 2009. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr. Infect. Dis. J. 28:717-723. doi:10.1097/INF .0b013e31819f1f50.
24. Han S, Kim J, Yim H, Hur J, Song W, Lee J, Jeon S, Hong T, Woo H, Yim DS 17 December 2012. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection. Antimicrob. Agents Chemother. doi 10.1128/AAC.01372-12.
25. Brett J, Chong O, Graham GG, Ray JE, Marriott D, Williams KM, Day RO. 2013. Antifungal use and therapeutic monitoring of plasma concentrations of itraconazole in heart and lung transplantation patients. Ther. Drug Monit. 35:133-136. doi:10.1097/FTD.0b013e318275fe69.
26. Cartledge JD, Midgely J, Gazzard BG. 1997. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J. Clin. Pathol. 50:477-480.
27. Cheomung A, Na-Bangchang K. 2011. HPLC with ultraviolet detection for the determination of chloroquine and desethylchloroquine in whole blood and finger-prick capillary blood dried on filter paper. J. Pharm. Biomed. Anal. 55:1031-1040. doi:10.1016/j.jpba.2011.03.001.
28. Kromdijk W, Mulder JW, Rosing H, Smit PM, Beijnen JH, Huitema AD. 2012. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. J. Antimicrob. Chemother. 67: 1211-1216. doi:10.1093/jac/dks011.
29. Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WC, van Altena R, Brouwers JR, Uges DR, Alffenaar JW 27 August 2012. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob. Agents Chemother. doi 10.1128/AAC.01054-12.
30. Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR. 2011. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879:1063-1070. doi:10.1016/j.jchromb.2011 .03.017.
31. Li W, Tse FL. 2010. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24:49-65. doi:10.1002/bmc.1367.
32. Vu DH, Alffenaar JW, Edelbroek PM, Brouwers JR, Uges DR. 2011. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr. Pharm. Des. 17:2931-2939.
33. Edelbroek PM, van der Heijden J, Stolk LM. 2009. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther. Drug Monit. 31:327-336. doi:10.1097/FTD.0b013e31819e91ce.
34. Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, Uges DR. 2010. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878:39-44. doi:10.1016/j.jchromb.2009.11 .017.
35. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CMV).May 2001. Guidance for industry: bioanalytical method validation. U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/Guidances/ucm0 70107.pdf.
36. Felce D, Perry J. 1995. Quality of life: its definition and measurement. Res. Dev. Disabil. 16:51-74.
37. Cohen SR, Mount BM, Tomas JJ, Mount LF. 1996. Existential well-being is an important determinant of quality of life. Evidence from the McGill Quality of Life Questionnaire. Cancer 77:576-586.
38. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. 1978. Studies with pain rating scales. Ann. Rheum. Dis. 37:378-381.
39. Emmons G, Rowland M. 2010. Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis 2:1791-1796. doi:10 .4155/bio.10.159.
40. Baietto L, D'Avolio A, Marra C, Simiele M, Cusato J, Pace S, Ariaudo A, De Rosa FG, Di Perri G. 2012. Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. J. Antimicrob. Chemother. 67:2645-2649. doi:10.1093/jac/dks285.
41. Kromdijk W, Mulder JW, Smit PM, Ter Heine R, Beijnen JH, Huitema AD. 12 December 2012. Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof of concept study. Antivir. Ther. doi:10.3851/IMP2501.
42. Cheung CY, van der Heijden J, Hoogtanders K, Christiaans M, Liu YL, Chan YH, Choi KS, van de Plas A, Shek CC, Chau KF, Li CS, van Hooff J, Stolk L. 2008. Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation. Transpl. Int. 21:140-145. doi:10.1111/j.1432-2277.2007.00584.x.